Leczenie molekularnie ukierunkowane chorych na zlośliwe glejaki mózgu


Author(s): Janusz Rolski, Bogdan Gliński, Pawel Blecharz, Agnieszka Chrostowska

Malignant gliomas are the most common primary brain tumours in adult patients. Despite modest improvement in survival, the prognosis is still far from expected in this disease. Molecularly directed (targeted) therapies investigated to date include inhibitors of the EGFR (epidermal growth factor receptor) and anti-antiangiogenic agent VEGFR (vascular endothelial growth factor receptor). Unfortunately, the number of patients with long-term response to this agents remains low. The results of already conducted and preliminary results of ongoing clinical trials assessing the role of monoclonal antibodies against EGFR and VEGF are presented. Rationale for such forms of treatment and of different options of targeted therapy are also discussed. It seems, that identification of biomarkers that will allow a more accurate prediction of which patients are likely to benefit from a specific treatment is of particular importance.

Share this article

Editors List

  • Osamu Tanaka

    Osamu Tanaka
    Assistant Professor,
    Department of Radiation Oncology
    Asahi University Hospital
    Gifu city, Gifu, Japan

  • Maher Abdel Fattah Al-Shayeb

    Department of Surgical Sciences, Ajman University, UAE

  • Andrzej Zdziennicki

    Institute of Gynecology and Obstetrics, Medical University of Lodz, I Clinic of Gynecology and Gynecological Oncology (Lodz, Poland)

  • Krzysztof Urbanski

    Head of the Oncology Gynecology Clinic, Oncology Center - Instytut im. Maria Sklodowska Curie, Department in Krakow (Krakow, Poland)

  • Andrzej Szawlowski

    Klinika Nowotworow Gornego Odcinka Uklad Digestii, Oncology Center - Institute (Warsaw, Poland)